Get the Stockscreener App
17.63
0.63%
0.11
After Hours:
17.74
0.11
+0.62%
Beam Therapeutics Inc stock is traded at $17.63, with a volume of 3.66M.
It is up +0.63% in the last 24 hours and down -16.72% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$17.52
Open:
$17.88
24h Volume:
3.66M
Relative Volume:
1.73
Market Cap:
$1.78B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-9.7403
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-1.29%
1M Performance:
-16.72%
6M Performance:
-45.59%
1Y Performance:
-24.53%
1-Day Range:
$17.03
$18.23
1-Week Range:
$16.65
$18.23
52-Week Range:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
17.63 | 1.77B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease - Pharmacy Times
Beam Therapeutics Stock Surges After FDA Grants RMAT Designation - MSN
Beam Therapeutics stock surges after FDA grants RMAT designation By Investing.com - Investing.com Canada
Beam Therapeutics stock surges after FDA grants RMAT designation - Investing.com
Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease - MarketScreener
Beam gains FDA Regenerative Medicine Advanced Therapy status for sickle cell treatment - Seeking Alpha
Beam Therapeutics' Sickle Cell Treatment Gets FDA's Generative Medicine Advanced Therapy Designation - MarketWatch
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy By Investing.com - Investing.com Australia
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam's Sickle Cell Gene Therapy Gets FDA Speed Boost After Strong Trial Data in 30 Patients - Stock Titan
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Will Beam Therapeutics Inc. benefit from government policyROI-Driven Capital Plans - thegnnews.com
Beam Therapeutics (NASDAQ:BEAM) Price Target Cut to $21.00 by Analysts at Barclays - MarketBeat
Beam Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsFree Access to Community - beatles.ru
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark - MSN
Beam Therapeutics: Analyst Maintains Buy Rating Amid Promising Trials and Solid Financials - AInvest
Beam Therapeutics: A Promising Genetic Medicine Player with Multiple Upcoming Catalysts - AInvest
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Leerink Partners Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $42 - 富途牛牛
Beam Therapeutics Receives Buy Rating from Leerink Partners with $42 Price Target - AInvest
Beam Therapeutics Reports Q2 2025 Financials, Promising BEAM-302 Results in AATD Trial and Completion of BEACON Trial for Sickle Cell Disease. - AInvest
Beam Therapeutics Reports Q2 Revenue Below Consensus, Highlights Clinical Progress in Priority Programs - AInvest
Beam Therapeutics: A Narrower Loss in Q2 2025—Sign of a Sustainable Turnaround or a Temporary Bounce? - AInvest
Beam Therapeutics 2025 Q2 Earnings Net Loss Widen Despite EPS Improvement - AInvest
BEAM: Barclays Lowers Price Target with Equal-Weight Rating | BE - GuruFocus
Positive Developments and Financial Strength Bolster Beam Therapeutics’ Buy Rating - TipRanks
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates - MSN
Beam Therapeutics Reports Q2 2025 Financial Results - TipRanks
Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Beam Therapeutics shares fall 1.59% intraday after Q2 net loss widens more than expected. - AInvest
Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com
Beam Therapeutics Q2 Net Loss Narrows, Revenue Falls - MarketScreener
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Beam Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Beam (BEAM) Advances in AATD Treatment with Promising BEAM-302 T - GuruFocus
BEAM Reports Q2 Revenue Below Consensus and Highlights Significa - GuruFocus
Beam Therapeutics Inc Reports Q2 2025 EPS of -$1.00, Beating Est - GuruFocus
Beam Therapeutics Q2 net loss widens more than expected - MarketScreener
Beam Therapeutics Inc. SEC 10-Q Report - TradingView
Earnings Flash (BEAM) Beam Therapeutics Posts Q2 $1 Loss, vs. FactSet Est of $1.11 Loss - MarketScreener
Beam Therapeutics Reports Positive Clinical Updates for BEAM-302 and BEAM-101, Financial Results for Q2 2025 - Quiver Quantitative
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) - The Manila Times
Beam Therapeutics Reports Second Quarter 2025 Financial - GlobeNewswire
Beam Therapeutics' AATD Treatment Achieves Major Clinical Milestone: 17 Patients Show Durable Disease Correction - Stock Titan
Beam Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
When is Beam Therapeutics Inc. stock expected to show significant growthBuild a diversified portfolio for steady growth - Jammu Links News
What makes Beam Therapeutics Inc. stock price move sharplyCapitalize on momentum-driven stocks - Jammu Links News
How many analysts rate Beam Therapeutics Inc. as a “Buy”Unlock real-time stock alerts for quick profits - Jammu Links News
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):